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LABOUR INDUCTION 
G Justus Hofmeyr, Baron B Matonhodze, Zarko Alfirevic, 
El izabeth Campbell, Marinda de Jager, Cheryl Nikodem 
Background. Misoprostol, a cheap, stable, orally active 
prostaglandin analogue, is effective for labour induction 
when administered either vaginally or orally, but uterine 
hyperstimulation an d rupture have been reported. Previous 
stud ies of oral misoprostol for labour induction have used 
fixed dosages 3 - 6-hourly. 
Objectives. To develop a new method of misoprostol use for 
labour induction using very small, frequen t, titrated oral 
dosages, and to p ilot effectiveness. 
Study design. Open clinical pilot study. 
Setting. Coronation Hospital, an academic hospital in 
Johannesburg, South Africa. 
Methods. We developed a method using 2-hourly titrated 
rnisoprostol doses commencing wi th 20 ~g, increased after 
three doses to 40 ~g. To administer such small doses we 
dissolved one rnisoprostol tablet in 200 ml water. A p ilot 
study of this method was undertaken in 25 women wi th 
various indications for induction of labour. 
Results. Eighteen women (72%) delivered vaginally wi thin 
32 hours of induction and two women developed uterine 
hyperstirnulation. The caesarean section rate was 20%. 
Conclusions. Women may respond to much smaller dosages 
of misoprostol than are currently in use. A multicentre 
randomised trial of this method is underway. We emphasise 
the dangers inherent in the current unregistered use of 
rnisoprostol in clinical practice. 
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Three years ago we drew attention in this journal to the 
dan gers of rnisoprostol use in the third trim ester of p regnancy. 1 
However, we continue to admit women with complications of 
misoprostol overdosage, including uterine rupture, to academic 
hospitals in Johannesburg. 
Induction of labour in the third trimester of pregnancy may 
be considered beneficial in many clinical circumstances. The 
risks include ineffective labour (failed ind uction), or excessive 
uterine activity which may cause fetal distress or uterine 
rupture. Either p roblem may lead to an increased risk of 
caesarean section. Unsuccessful labour induction is most likely 
when the cerv ix is unfavourable, and in this circumstance 
prostaglandin preparations have proved to be beneficial.' Those 
prostaglandins, which have been registered for cervical 
ripening and labour induction, are expensive and unstable and 
require refrigerated storage. 
Misoprostol (Cytotec, Searle) is a methyl ester of 
prostaglandin El registered for use in the preventi on and 
treatment of peptic ulcer d isease ca used by prostagland in 
synthetase inhibitors. It is inexpensive, easily s tored at room 
tempera ture and has few systemic side-effects. 
Current experience with misoprostol used for labour 
induction h as been reviewed recen tly.3·' Al though in most 
s tudies misoprostol seemed to be a t least as effecti ve as 
conventional methods, widely varying dosage regimens and 
smaJJ numbers of women studied do not allow for adequa te 
assessment of safety. The widespread use of misoprostol in 
clinical practice in this country and elsewhere, using arbitrary 
dosages and withou t registration or proper surveillance for 
ad verse even ts, is cause for grave concern,' as a re reports of 
complications such as u terine rupture. 
Although m ost resea rchers and clinicians have cho en the 
vaginal route for rnisoprostol administration, oral 
administration may have several ad vantages. Administration is 
easier and may be more acceptable to women. Absorption is 
more rapid and possibly more predictable. The reported mean 
peak serum misoprostol acid level fo llowing o ral 
administra tion was 227 pg / mJ after 34 minutes compared with · 
165 pg / mJ after 80 minutes fo r the vaginal route. Vaginally 
absorbed serum kvels are more prolonged ' The shorter half-
life when given ora lly may be advantageous in the event of 
uterine h yperstimulation . On the o ther hand, the d irect local 
effect of vaginal misoprostol on cervical softening may be 
advantageous. 
Randomised trials of oral misoprostol reviewed to da te have 
used fixed misoprostol regimens with a wide range of dosages, 
from 50 }.lg 4-hourly to 200 ~g every 6 hours.' 
Based on the knowledge that uterine sensi tivity is extremely 
variable between individuals, and in the same p erson over 
time, we adopted the principle that misopros tol should be 
administered orally in small, frequent dosages, titrated against 
the uterine response. This is analogous to the conventional 
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titrated use of oxytocin. To overcome the difficulty of breaking 
the misoprostol tablets accurately into small fragments, we 
decided to use one misoprostol tablet (200 !lg) dissolved in a 
medicine bottle with 200 ml water (1 !lg per ml solution). The 
bottle was shaken well before each administration. 
M ETHODS 
We conducted a pilot study at Coronation Hospital, 
Johannesburg, to assess the effectiveness of this novel approach 
in pregnant women with singleton, cephalic presentation 
requiring labour induction at term. The study was approved by 
the Committee for Research on Human Subjects of the 
University of the Witwatersrand, and informed consent was 
signed by all participants. The initial commencing dosage 
chosen was 40 Jlg 2-hourly, but uterine hyperstimulation was 
observed in the first woman studied. A revised .protocol was 
applied to all women irrespective of parity, cervical score or 
membrane status (intact or ruptured). Labour was induced 
with 2-hourly oral misoprostol solution, 20 ).lg for the first three 
doses, then increased to 40 Jlg repeated 2-hourly until adequate 
contractions were achieved. Once uterine activity became 
adequate no further rnisoprostol was given. If contractions 
subsequently became inadequate, labour augmentation with 
hourly misoprostol solution was to be started at 5 ).lg, 
increasing to 10 and then 20 ).lg, and repeated until adequate 
uterine contractions occtrrred. 
RESULTS 
The pilot study using the above dosages included 25 women 
due for labour induction for hypertension (7), post-term 
pregnancy (8), impaired fetal growth (4), prelabour rupture of 
membranes (4), rhesus disease (1) and pruritus (1). The cervical 
score was < 7 in 18 women. The results are shown in Table I. 
The median dosage of rnisoprostol used was 150 !lg (range 50 -
400 ).lg). Once labour was established, augmentation was not 
reqi.Ured in any case. The method was favourably received by 
the women and staff. 
Table I . Results of labour induction with titrated oral rnisoprostol 
solution 
lumber of 
Outcome women (N = 25) 
Active labour within 12 hours 12 
Active labour within 24 hours 23 
Vaginal delivery within 24 hours 14 
Vaginal delivery within 32 hours 1 
Caesarean section 5 
Uterine hyperstimulation 2 
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% (95% CI) 
48 (28- 69) 
92 (74- 99) 
56 (35 - 76) 
72 (51 - 88) 
20 (7 -41) 
8 (1 - 26) 
DISCUSSIO N 
The results of this small pilot study have confirmed the wide 
range of individual responsiveness to rnisoprostol, supporting 
the principle of using small, frequent doses titrated against 
uterine contractions. The regimen chosen appeared to represent 
a reasonable balance between achieving effectiveness and 
avoiding excessive hyperstimulation. 
On the basis of these results we are conducting a large 
randornised multicentre trial to assess the effectiveness and 
safety of this regimen compared with conventional 
dinoprostone vaginal gel, and at one centre with extra-amniotic 
Foley catheter bulb placement. Depending on the results, a 
further avenue of investigation may be the use of a single small 
dose of misoprostol vaginally for locally mediated effects on 
the cervix, followed by titrated oral rnisoprostol solution for 
fine-turling of uterine contractions. 
The importance of this report is that it shows that women 
usually respond to much smaller doses of rnisoprostol than are 
currently in common use, and to call again for caution in the 
use of rnisoprostol in the third trimester. 
We acknowledge support from the University of the 
Witwatersrand, the South African Medical Research Council and 
Liverpool University, UK. 
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